BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therap

Barclays analyst Eliana Merle maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and lowe

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeB

PALO ALTO, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeB

BridgeBio Pharma, Inc. (Nasdaq: BBIO) ("BridgeBio" or the "Company"), a commercial-s

- Accepted for Priority Review with a PDUFA target action date of February 4, 2027; being granted Pr

- October 6 YouTube premiere featuring Sway Calloway, Howard “H” White and leading medical and cultu

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated

- In exploratory analyses at Month 12, among individuals with LGMD2I/R9 (FKRP-related) with elevated

BridgeBio Pharma NASDAQ: BBIO expects 2027 to be a transformative year as it expands from one commer

BridgeBio Pharma (NASDAQ: BBIO) expects 2027 to be a transformative year as it expands from one comm

BridgeBio Pharma, Inc. (BBIO) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3r

- In the first peer-reviewed, real-world, contemporary, comparative effectiveness study of TTR stabi

PALO ALTO, Calif., Sept. 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge

BridgeBio Pharma, Inc. (BBIO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Tr

VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of BridgeBio Pharma, Inc. (NASDAQ: BB

BridgeBio Pharma, Inc. (BBIO) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference

BridgeBio pharma has delivered multiple clinical and commercial successes, yet shares have repeatedl

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with

BridgeBio Pharma, Inc. (BBIO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

BridgeBio Pharma (BBIO) reported earnings 30 days ago. What's next for the stock?

BridgeBio Pharma shares 52-week data on oral infigratinib for achondroplasia, showing improvements i

- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against pla

- Treatment with oral infigratinib for 52 weeks in PROPEL 3 resulted in favorable trends against pla

Frazier Life Sciences Management L.P. decreased its stake in shares of BridgeBio Pharma, Inc. (NASDA

PALO ALTO, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“Bridge

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with

Mizuho analyst Salim Syed maintains BridgeBio Pharma (NASDAQ:BBIO) with a Outperform and raises t

Trump secures drug pricing deals with nine pharma companies as Kennedy reveals intense pressure from

https://www.whitehouse.gov/fact-sheets/2026/08/fact-sheet-president-donald-j-trump-announces-deal-wi

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a biopharmaceut

This whale alert can help traders discover the next big trading opportunities. Whales are entities w

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio"), a commercial-stage, multi-product biopha

Truist Securities analyst Danielle Brill maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and

Canaccord Genuity analyst Whitney Ijem maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and ra

JP Morgan analyst Anupam Rama maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and rais

B of A Securities analyst Geoff Meacham maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and r

TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and raises t

Morgan Stanley analyst Sean Laaman maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

Piper Sandler analyst Biren Amin maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and r

Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and

BridgeBio Pharma (NASDAQ:BBIO) reported quarterly losses of $(0.78) per share which missed the analy

Applied Materials, Coherent, CoreWeave and eight other names carry double-digit implied earnings mov

BridgeBio Pharma, Inc. (NASDAQ:BBIO) ("BridgeBio" or the "Company"), a commercial-st

Citigroup analyst Eric Joseph maintains BridgeBio Pharma (NASDAQ:BBIO) with a Neutral and raises

Wall Street analysts change outlook on top names. Complete view of analyst rating changes including

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BridgeBio Pharma (NASDAQ:BBIO) with

Ionis and AstraZeneca's Phase 3 ATTR-CM trial misses its primary goal, analyst says the outcome